OncRef

Clinical Trial: NCT06333678

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Status:

TERMINATED

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-09-02

Study Overview

Brief Summary

In this study, the researchers will look at whether having participants switch from durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The researchers will see whether this switch to sotorasib can control LANSCLC longer compared to the treatment approach of staying on durvalumab (and not switching to sotorasib).

Official Title

A Randomized Phase II Study of Sotorasib Versus Continued Consolidation Durvalumab in Patients With KRAS G12C Mutant Locally Advanced Non-small Cell Lung Cancer (LANSCLC) With Persistent ctDNA Defined Minimal Residual Disease

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Sotorasib

Other Study ID Numbers

  • 22-321

Start Date (Actual)

2024-03-20

Primary Completion Date (Actual)

2026-01-27

Study Completion Date (Actual)

2026-01-27

Enrollment (Actual)

10

Study Type

Interventional

Phase

Phase 2